Leidos Holdings, Inc LDOS reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.
The results reflect increased demand across all customer segments, especially for digital modernization and medical examination solutions.
The company clocked an adjusted EPS of $2.03, up 28% year-over-year, beating the consensus of $1.67.
Adjusted net income was $283 million for the second quarter, up 28% year-over-year.
Adjusted EBITDA was $451 million, up 21% year-over-year. Adjusted EBITDA margin of 11.5% increased from 10.3% in the third quarter of 2022.
Net bookings totaled $7.9 billion in Q3, representing a book-to-bill ratio 2.0.
As a result, the backlog at the end of the quarter was $38.0 billion, of which $9.0 billion was funded.
Leidos held $750 million in cash and equivalents by the end of the quarter.
Outlook: Leidos raised FY23 revenue guidance to $15.1 billion - $15.3 billion (prior $14.9 billion-$15.2 billion). The analyst consensus stands at $15.12 billion.
The company increased its FY23 adj EPS outlook to $6.80 - $7.10 (prior $6.40 - $6.80) versus the $6.68 consensus.
Price Action: LDOS shares are trading higher by 2.70% at $94.27 premarket on the last checked Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.